Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis
Clinical trial NCT00870740 · COMPLETED
Trial details
- NCT number
- NCT00870740
- Sponsor
- Biogen
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-02-01
- Primary completion
- 2012-05-01
- Enrollment
- 517
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.